PriceTargets.com logo

PolyPid - PYPD Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.00
  • Forecasted Upside: 238.03%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$3.55 As of 11/15/2024 01:00 AM ET
▲ +0.13 (3.80%)

This chart shows the closing price for PYPD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New PolyPid Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PYPD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PYPD

Analyst Price Target is $12.00
▲ +238.03% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for PolyPid in the last 3 months. The average price target is $12.00, with a high forecast of $14.00 and a low forecast of $10.00. The average price target represents a 238.03% upside from the last price of $3.55.

This chart shows the closing price for PYPD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in PolyPid. This rating has held steady since August 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/4/2024Craig HallumInitiated CoverageBuy$10.00
10/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
8/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
6/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
5/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00
5/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00
10/12/2023HC WainwrightInitiated CoverageBuy
9/7/2022BarclaysDowngradeOverweight ➝ Equal Weight$660.00 ➝ $75.00
9/6/2022Raymond JamesDowngradeStrong-Buy ➝ Outperform$450.00 ➝ $120.00
8/11/2022BMO Capital MarketsLower TargetOutperform$810.00 ➝ $750.00
2/11/2022Raymond JamesLower TargetStrong-Buy$690.00 ➝ $510.00
12/16/2021JMP SecuritiesReiterated RatingBuy$450.00
10/11/2021JMP SecuritiesReiterated RatingBuy
9/14/2021JMP SecuritiesInitiated CoverageOutperform$420.00
7/30/2021Cantor FitzgeraldInitiated CoverageOverweight$720.00
11/24/2020Raymond JamesUpgradeOutperform ➝ Strong-Buy
8/21/2020Raymond JamesReiterated RatingBuy
8/10/2020Alliance Global PartnersInitiated CoverageBuy$810.00
7/21/2020Raymond JamesInitiated CoverageOutperform$690.00
7/21/2020BarclaysInitiated CoverageOverweight$660.00
7/21/2020BMO Capital MarketsInitiated CoverageOutperform$900.00
(Data available from 11/17/2019 forward)

News Sentiment Rating

0.37 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/21/2024
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2024
  • 2 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/17/2024

Current Sentiment

  • 2 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

PolyPid logo
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Read More

Today's Range

Now: $3.55
Low: $3.49
High: $3.56

50 Day Range

MA: $3.47
Low: $3.15
High: $3.68

52 Week Range

Now: $3.55
Low: $2.95
High: $9.20

Volume

10,411 shs

Average Volume

7,607 shs

Market Capitalization

$17.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31

Frequently Asked Questions

What sell-side analysts currently cover shares of PolyPid?

The following sell-side analysts have issued research reports on PolyPid in the last twelve months: Craig Hallum, and HC Wainwright.
View the latest analyst ratings for PYPD.

What is the current price target for PolyPid?

0 Wall Street analysts have set twelve-month price targets for PolyPid in the last year. Their average twelve-month price target is $12.00, suggesting a possible upside of 238.0%. HC Wainwright has the highest price target set, predicting PYPD will reach $14.00 in the next twelve months. Craig Hallum has the lowest price target set, forecasting a price of $10.00 for PolyPid in the next year.
View the latest price targets for PYPD.

What is the current consensus analyst rating for PolyPid?

PolyPid currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PYPD will outperform the market and that investors should add to their positions of PolyPid.
View the latest ratings for PYPD.

What other companies compete with PolyPid?

Other companies that are similar to PolyPid include iCAD, InspireMD, Alpha Pro Tech, Nutriband and Milestone Scientific. Learn More about companies similar to PolyPid.

How do I contact PolyPid's investor relations team?

PolyPid's physical mailing address is 18 HASIVIM STREET P.O BOX 7126, PETACH TIKVA L3, 4959376. The company's listed phone number is 972-74-719-5700 and its investor relations email address is [email protected]. The official website for PolyPid is www.polypid.com. Learn More about contacing PolyPid investor relations.